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Neurodegeneration in diseases caused by altered metabolism of mammalian prion protein (PrP) can be averted by
reducing PrP expression. To identify novel pathways for PrP down-regulation, we analyzed cells that had adapted to the
negative selection pressure of stable overexpression of a disease-causing PrP mutant. A mutant cell line was isolated that
selectively and quantitatively routes wild-type and various mutant PrPs for ER retrotranslocation and proteasomal
degradation. Biochemical analyses of the mutant cells revealed that a defect in glycosylphosphatidylinositol (GPI) anchor
synthesis leads to an unprocessed GPI-anchoring signal sequence that directs both ER retention and efﬁcient retrotrans-
location of PrP. An unprocessed GPI signal was sufﬁcient to impart ER retention, but not retrotranslocation, to a
heterologous protein, revealing an unexpected role for the mature domain in the metabolism of misprocessed GPI-
anchored proteins. Our results provide new insights into the quality control pathways for unprocessed GPI-anchored
proteins and identify transamidation of the GPI signal sequence as a step in PrP biosynthesis that is absolutely required
for its surface expression. As each GPI signal sequence is unique, these results also identify signal recognition by the
GPI-transamidase as a potential step for selective small molecule perturbation of PrP expression.
INTRODUCTION
A wide range of diseases are caused by aberrant folding,
processing, trafﬁcking, or degradation of proteins in the
secretory pathway (Cohen and Kelly, 2003; Hebert and Mo-
linari, 2007; Otsu and Sitia, 2007). Protein-folding diseases
are typically dominant gain-of-function disorders whose
pathogenesis is intimately tied to the expression level of the
misfolded protein. It is therefore of substantial importance
to understand the cellular quality control pathways that
discriminate properly folded from misfolded proteins to
regulate their maturation. Such studies would provide mo-
lecular level insights into the basis of protein-folding dis-
eases and could eventually be exploited to manipulate qual-
ity control and inﬂuence disease pathogenesis. However, the
near ubiquitous use of these quality control pathways makes
identifying sufﬁciently selective points for potential pharma-
cologic perturbation a daunting challenge.
Several dramatic examples of dominant gain-of-function
disorders are caused by misfolding of PrP, a widely ex-
pressed cell surface glycoprotein of unknown function
(Prusiner, 1998; Aguzzi and Heikenwalder, 2006; Wads-
worth and Collinge, 2007). These diseases can be inherited
through mutations in Prnp (the gene that codes for PrP) or
acquired via a transmissible agent composed of a misfolded
isoform of PrP, termed PrPSc. Exogenous PrPSc is capable of
converting the normal cellular isoform (PrPC) into addi-
tional PrPSc molecules, leading to its accumulation and gen-
eration of additional transmissible agent. In the familial
diseases, PrP mutations typically cause accumulation of mis-
folded PrP through poorly understood mechanisms that in
some cases also generate PrPSc. Thus, altered PrP folding,
metabolism, and accumulation are the proximal causes of
both familial and transmissible prion diseases.
Although the downstream pathways leading from mis-
folded PrP to cellular toxicity are not known, it is clear that
ongoing PrP expression is an absolute prerequisite for neu-
ronal cell death and disease progression (Bueler et al., 1993;
Prusiner et al., 1993; Brandner et al., 1996). Indeed, not only
is there a tight correlation between expression level and the
time course of both genetic (Telling et al., 1996; Chiesa et al.,
1998; Hegde et al., 1999) and transmissible prion diseases
(Prusiner et al., 1990, 1993; Bueler et al., 1993, 1994), but
reducing PrP expression even after the onset of symptoms
can reverse disease (Mallucci et al., 2003, 2007). Preventing
accumulation of more misfolded material by reducing PrP
expression allows normal metabolic pathways to restore
homeostasis by clearing various disease associated PrP
forms (including PrPSc), despite their often aggregated state
(Safar et al., 2005). Thus, an attractive and viable strategy for
this class of protein folding diseases is to reduce PrP expres-
sion (Mallucci and Collinge, 2005). Even a modest reduction
in expression can evidently have a substantial impact on
disease progression because mice lacking one copy of the
Prnp gene exhibit markedly longer incubation times after
infection with PrPSc (Bueler et al., 1993; Prusiner et al., 1993;
Bueler et al., 1994; Manson et al., 1994). However, the path-
ways that regulate total cellular levels of PrP, particularly
those potentially amenable to selective modulation, are
poorly studied and incompletely understood.
As transmissible disease pathogenesis requires that PrPC
reach the cell surface (at least transiently; (Caughey and
This article was published online ahead of print in MBC in Press
(http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E08–01–0087)
on May 28, 2008.
Address correspondence to: Ramanujan S. Hegde (hegder@mail.
nih.gov).
© 2008 by The American Society for Cell Biology 3463Raymond, 1991; Borchelt et al., 1992), attenuation of PrP
expression at any of the earlier biosynthetic steps of tran-
scription, translation, maturation, or trafﬁcking are poten-
tially useful. An especially attractive strategy is to exploit
normal quality control (QC) pathways that are designed to
recognize and route proteins for degradation. In the case of
PrP, the primary site of QC is presumably in the endoplas-
mic reticulum (ER) lumen, the site of secretory and mem-
brane protein biogenesis and maturation. The ER contains
multiple QC pathways composed of different (and some-
times overlapping) subsets of chaperones that operate in
parallel to handle different types of substrates. However, the
parameters used by any these QC pathways to distinguish
normal from abnormal proteins are incompletely under-
stood. The recognition motifs include diverse features such
as glycan structure (e.g., the chaperones calnexin and calre-
ticulin; Ellgaard and Helenius, 2001; Hebert and Molinari,
2007), unpaired or inappropriately bonded cysteines (oxido-
reductases such as protein disulﬁde isomerase [PDI]; Hata-
het and Ruddock, 2007), and surface-exposed hydrophobic
patches (most chaperones, including BiP and PDI; Ni and
Lee, 2007). Thus, it is thought that misfolding or misprocess-
ing leads to recognition and prolonged interactions with
speciﬁc chaperones that can initiate substrate routing into
ER-associated degradation (ERAD) pathways (McCracken
and Brodsky, 2005; Meusser et al., 2005).
After chaperone-mediated targeting for ERAD, a decisive
step in misfolded protein degradation is its export to the
cytosol via a putative retrotranslocation channel. Although
the identity and nature of the retrotranslocation channel(s)
remain contentious (Meusser et al., 2005), it is thought that
once substrates are exposed to the cytosol, they are ubiqui-
tinated, extracted from the membrane, deglycosylated (in
the case of glycoproteins), and degraded by the proteasome.
Thus, the combination of QC and ERAD pathways are de-
signed to recognize, export, and degrade proteins from the
ER, and substrate engagement of this pathway is one way to
reduce functional expression of a secretory or membrane
protein. In fact, examples of protein levels being regulated at
the level of QC and ERAD have been described (e.g., HMG-
CoA reductase; Hampton, 2002; and apolipoprotein B; Da-
vidson and Shelness, 2000), highlighting the utility of these
systems as a means of physiologically and pharmacologi-
cally controlling gene expression.
Unfortunately, PrP seems to be especially refractory to
recognition, retrotranslocation, and/or degradation by
ERAD even when its maturation is impaired in any of sev-
eral ways. For example, mutations in one or both N-linked
glycosylation sites is entirely permissive for PrP trafﬁcking
out of the ER, does not substantially reduce steady-state
levels of PrP in transgenic and knock-in mice and permits
interaction with exogenous PrPSc to support prion replica-
tion in cell culture and in mice (Neuendorf et al., 2004;
Cancellotti et al., 2005). Mutants that disrupt the single di-
sulﬁde bond in PrP (Yanai et al., 1999) or PrP made during
reducing conditions (Kang et al., 2006), despite being mis-
folded and incompetent for trafﬁcking to the cell surface, are
degraded inefﬁciently and instead aggregate intracellularly.
Deletion of the GPI-anchoring signal sequence (Campana et
al., 2007) or conversion to a transmembrane domain
(Taraboulos et al., 1995; Kaneko et al., 1997) both result in
PrPs that escape QC in the ER and are either secreted or
expressed on the cell surface, respectively. Furthermore,
various human disease-causing mutants are only partially if
at all degraded by ERAD, despite their apparent misfolding
or altered topology (Hegde et al., 1998; Ma and Lindquist,
2001; Yedidia et al., 2001; Drisaldi et al., 2003). Finally, a wide
range of artiﬁcial mutations and deletions are readily toler-
ated and lead to ER export (Muramoto et al., 1996; Shmerling
et al., 1998; Supattapone et al., 2001; Baumann et al., 2007; Li
et al., 2007; Hegde et al., 1998) or in some cases, ER storage
disease (Muramoto et al., 1997). Thus, in no situation is
mutated, misfolded, or misprocessed PrP recognized and
efﬁciently degraded by ERAD. In fact, it has been suggested
that retrotranslocation of PrP (even at relatively low levels)
could be highly cytotoxic due to the transient generation of
cytosolic PrP, perhaps explaining why it is typically such a
poor substrate for ERAD. Hence, a major unresolved issue is
how or whether PrP can be routed quantitatively for ERAD
and whether this would be tolerated, beneﬁcial, or detrimen-
tal to cells.
Here, we report the unexpected discovery of a mutant cell
line that routes both wild-type and mutant PrPs quantita-
tively for retrotranslocation and proteasome-dependent
degradation without any obvious toxicity. This rerouting
was due to an unprocessed GPI-anchoring signal sequence
that, in combination with the PrP mature domain, forms a
remarkably efﬁcient ERAD substrate. This study has there-
fore led to the identiﬁcation of a previously unanticipated
site for modulating PrP expression, described a robust
model system for the study of PrP QC and retrotransloca-
tion, and more generally, led to new insights into the deter-
minants for QC of GPI-anchored proteins in the ER.
MATERIALS AND METHODS
Cells, Plasmids, and Reagents
Neuro2a (N2a) cells were cultured in DMEM containing 10% FBS in a hu-
midiﬁed 37°C incubator at 5% CO2. L-cells, a kind gift from Dr. J. Bonifacino
(NIH) and have been previously described (Sugiyama et al., 1991), were
cultured in RPMI 1640 medium containing 10% FBS at 5% CO2. Stable cell
lines were generated by selection in 200 g/ml Zeocin (Invitrogen, Carlsbad,
CA) for 4 wk, followed by subcloning of individual colonies. PrP expression
levels were analyzed in several individual clones by both immunoblotting
and immunoﬂuorescence using the 3F4 antibody. One clone expressing wild-
type PrP (termed C3) and one that expressed PrP(A117V) at very low steady-
state levels (termed A4) were chosen for detailed characterization. All exper-
iments involving transient transfection were transfected with Lipofectamine
2000 (Invitrogen) according to manufacturer’s directions and analyzed 18–24
h after transfection. Plasmids encoding wild-type and mutant PrPs in a
pCDNA3.1-based vector (Invitrogen) have either been described (Rane et al.,
2004) or generated from these constructs using standard site-directed mu-
tagenesis. Hemagglutinin (HA)-tagged PrPs were generated from the non-
tagged constructs by insertion of synthetic oligonucleotides encoding the
epitope at the Bsu36I site (between residues 51 and 52) of PrP. PrPGPI was
constructed by deletion of the C-terminal 23 amino acids from the PrP coding
region. RFP-KDEL, VSVG-GFP, and GFP-GPIFR constructs have been previ-
ously described (Presley et al., 1997; Nichols et al., 2001; Snapp et al., 2006) and
were kind gifts from J. Lippincott Schwartz (NIH). ETBR-GFP was a kind gift
from Dr. R. Schu ¨lein (Forschungsinstitut fu ¨r Molekulare Pharmakologie, Ber-
lin) and has been previously described (Grantcharova et al., 2002). Green
ﬂuorescent protein (GFP)-GPI-Chinese hamster ovary (CHO) shown in Figure
7h a saD 3N change at position 36 of GFP to introduce a consensus site for
glycosylation. Two other constructs were also generated to introduce consen-
sus sites at other positions (L3T at position 137, and DK3YT at positions 211
and 212) and gave identical results to those shown in Figure 7. GFP-GPIPrP
was prepared in a pCDNA1.3-based vector and encodes residues 1-40 of
bovine preprolactin fused to the complete GFP sequence followed by residues
231-254 of hamster PrP. PrP(S232W) was generated by site-directed mutagen-
esis of hamster PrP. PrP-Qa was generated by replacing the GPI signal
sequence of HA-tagged hamster PrP (see above) with the complete GPI-
anchoring sequence of the Qa protein.
Antibodies were described previously or from the following sources: 3F4
mouse monoclonal against PrP (Signet Laboratories, Dedham, MA); PDI (Stress-
Gen, San Diego, CA); and GFP (Stefanovic and Hegde, 2007). The PrP-A rabbit
antiserum against PrP was generated (Lampire Biological Laboratories, Pipersville,
PA) against a synthetic peptide (KKRPKPGGWNTGGSRYC) conjugated to key-
hole limpet hemocyanin using standard protocols. Immunoblotting using
total brain homogenates from hamster and mouse showed reactivity to only
PrP when compared with other PrP antibodies. This antibody reacts against
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against human, mouse, and hamster PrP. Dithiothreitol (DTT) and tunicamy-
cin were from Sigma (St. Louis, MO) and were dissolved in water. Thapsi-
gargin, brefeldin A (BFA), MG132, and kifunensine were from Calbiochem
(La Jolla, CA) and were dissolved in DMSO, ethanol (BFA) or water
(kifunensine). Inhibitor concentrations used are indicated in the corre-
sponding ﬁgure legends. Concanavalin A-Sepharose was obtained from
Amersham-Pharmacia (Piscataway, NJ. All enzymes for cloning were ob-
tained from New England Biolabs (Beverly, MA) with the exception of Pfu
polymerase, which was from Stratagene (La Jolla, CA).
Biochemical Analyses
Metabolic labeling of cells, pulse-chase analysis and immunoprecipitations
were performed as previously described (Rane et al., 2004; Kang et al., 2006).
In general, cells were preincubated for 30 min in serum-free media lacking
methionine and cysteine before addition of 35S-Translabel to initiate the pulse.
Chase was initiated by replacing the labeling media with unlabeled complete
media. Inhibitors used in pulse-chase experiments were added at the follow-
ing times before the pulse labeling: 30 min for BFA and kifunensine,2hf o r
MG132 and tunicamycin, 10 min for DTT, and 1 min for thapsigargin. Unless
otherwise indicated in the ﬁgure legends, all inhibitors except thapsigargin
(an irreversible inhibitor) were maintained for the duration of the chase. For
immunoprecipitation (IP) under denaturing conditions, cells were lysed in 1%
SDS, 0.1 M Tris, pH 8, and heated immediately to 100°C in a boiling water
bath to fully denature all proteins. After shearing the nucleic acids by re-
peated vortexing, lysates were diluted 10-fold in ice-cold IP buffer (50 mM
HEPES, pH 7.4, 100 mM NaCl, and 1% Triton X-100) before addition of
antibodies and protein A-agarose, as previously described (Kang et al., 2006).
Nondenaturing IPs were performed on cells lysed directly in cold IP buffer on
ice. Lysates were clariﬁed by centrifugation in a microcentrifuge to remove
debris and IPed with the relevant antibody and protein A beads (Kang et al.,
2006). For sequential IPs, the products of a nondenaturing IP were denatured
in 1% SDS, 0.1 M Tris, pH 8, boiled, and diluted 10-fold in IP buffer before
adding the second antibody. Preparation of total cell lysates and solubility
assays for PrP were performed as previously described (Rane et al., 2004).
For separation of hydrophilic and hydrophobic proteins by Triton X-114
(TX-114; Sigma), cells grown in six-well plates were rinsed in PBS and lysed
in TX-114 lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, and
1% TX-114) on ice. Cell lysates were homogenized using 25-gauge aluminum
hypodermic needles (Monoject; Kendall, Covidien, Mansﬁeld, MA) and
placed at 37°C for 5 min to allow phase separation. After centrifugation for 5
min, the hydrophilic (top) and hydrophobic (bottom) phases were carefully
transferred to fresh tubes for analysis. PrP glycosylation status was assessed
by endoglycosidase H (EndoH) or PNGase F digestion: cell lysates made in
1% SDS, 0.1 M Tris, pH 8, were diluted in buffer containing 1% -mercapto-
ethanol/0.05 M Tris, pH 6.8, and heated to 100°C to reduce and denature all
proteins. For EndoH digestion, samples were cooled and diluted with G5
buffer (New England Biolabs) to a ﬁnal concentration of 0.1% SDS, 20 mM
Tris, and 50 mM citrate, pH 5.5, before incubation with 5000 U of EndoH for
4 h at 37°C. For PNGase digestion, Triton X-100 (Sigma) was added to a ﬁnal
concentration of 1% to the cooled cell lysates before incubation with 5000 U of
PNGase for4ha t37°C. After digestion with either enzyme, samples were
precipitated using trichloroacetic acid (TCA) according to standard protocols,
and recovered protein pellets were dissolved in equal volumes of 1% SDS,
and 0.1 M Tris, pH 8. SDS-PAGE separation of proteins and immunoblotting
was performed as previously described (Fons et al., 2003). Quantiﬁcation of
pulse-chase experiments utilized a Typhoon Phosphorimager and accompa-
nying software (Molecular Dynamics, Sunnyvale, CA) and autoradiographs
on Kodak BioMax ﬁlm (Eastman Kodak, Rochester, NY) were digitized using
Adobe Photoshop for preparation of ﬁgures (San Jose, CA).
Immunoﬂuorescence Microscopy
Fluorescence microscopy images were obtained using a Zeiss LSM510 confo-
cal microscope (Thornwood, NY) with accompanying image acquisition soft-
ware. Imaging conditions and quantitative analyses of localization were as
reported previously (Rane et al., 2004) with the following exceptions: a con-
focal slice corresponding to 2 Airy units and a 63 oil objective were used in
the acquisition of all images; for indirect immunoﬂuorescent detection of PrP,
an anti-mouse secondary antibody conjugated to Alexa Fluor-488 (Invitrogen)
was used at 1:1000 dilution.
Glycolipid Analysis
Labeling and extraction of glycolipids was performed as previously (Leman-
sky et al., 1991) with some modiﬁcations. Brieﬂy, 60–90% conﬂuent cells in
10-cm plates were rinsed twice in glucose-free medium and incubated in
RPMI 1640 medium without glucose containing 10% dialyzed FBS and 10
g/ml tunicamycin for1ha t37°C. Each dish of cells was labeled with 0.25
mCi/ml [3H]mannose (Perkin Elmer-Cetus, Norwalk, CT) for2ha t37°C,
rinsed once in PBS, scraped into a polypropylene tube, sedimented, and
extracted twice with chloroform-methanol-water (CMW; 10:10:3 ratio). The
pooled extracts were dried under vacuum, dissolved in water-saturated 1-bu-
tanol and extracted with butanol-saturated water. The aqueous phase was
then re-extracted in butanol, and the pooled butanol phases were dried under
vacuum to a volume of 50 l and spotted onto TLC plates (Merck, White-
house Station, NJ). Chromatograms were developed in CMW, dried in air,
sprayed with Enhance ﬂuorography reagent (Dupont, Wilmington, DE) and
exposed to ﬁlm.
RESULTS
Isolation of a Mutant Cell Line with Altered PrP
Expression
On the application of long-term negative selection pressure,
somatic cell lines often acquire mutations that partially or
completely alleviate the impediment to normal growth. Un-
derstanding the genetic or biochemical basis of speciﬁc ad-
aptations to a selection pressure can reveal new and unan-
ticipated parameters that inﬂuence a speciﬁc cellular
process. Indeed, biochemical and genetic analysis of somatic
cell mutants isolated by imposed selection pressure have
provided critical insight into such diverse areas as choles-
terol metabolism (Goldstein et al., 2002) and protein trafﬁck-
ing (Hyman, 1988; Lemansky et al., 1991; Hirose et al., 1992;
Ohtsuka et al., 1993; Ghaedi et al., 1999). A comparable
approach should also be useful in identifying posttranscrip-
tional pathways that regulate cellular PrP levels. We there-
fore analyzed PrP expression in clonal lines generated by
stable transfection of a mouse neuroblastoma cell line (N2a)
with disease-causing PrP mutants expressed behind the
strong and constitutive CMV promoter. Although most
clones that show poor expression are presumably due to low
transgene copy number, recombination, or site of integra-
tion, we reasoned that at least some may be due to somatic
mutations induced by selection pressure to down-regulate
mutant PrP expression.
The disease-causing PrP(A117V) mutant can be expressed
in cultured cells upon transient transfection without any
obvious differences from wild-type PrP in expression level,
localization, solubility, glycosylation pattern, or metabolism
(Figure 1A). However, during the isolation of stable cell lines
expressing PrP(A117V), a signiﬁcant number of clones had
poor or no expression. Our interest was drawn to one such
clone, termed A4, that not only showed very low steady-
state levels, but exclusively immature and intracellular PrP
glycoforms (Figure 1, B and C). Surprisingly, mature forms
of wild-type mouse PrP (MoPrP) endogenously expressed
by the parental N2a cell line were no longer detectable in A4
cells (Figure 1B). Hence, expression and processing of both
the transgene-expressed PrP(A117V) and endogenous
MoPrP were altered in A4 cells, suggesting a cellular, rather
than a transgene mutation. This was conﬁrmed by demon-
strating altered expression patterns in A4 cells, but not in
parental N2a cells, of transiently transfected plasmids en-
coding either wild-type PrP or PrP(A117V; Figure 1D). Not
only are the exogenously transfected PrPs expressed at
lower steady-state levels in A4 cells, but they show only
immature glycoforms by SDS-PAGE (Figure 1D), complete
sensitivity to EndoH (Figure 1E), and an exclusively ER
localization (Figure 1F). These data together indicate that
both endogenously and exogenously derived wild-type or
mutant PrPs fail to be expressed as mature, glycosylated, cell
surface molecules in A4 cells. Instead, the low level, exclu-
sively immature, ER-restricted PrP species was suggestive of
altered PrP biosynthesis, processing, or trafﬁcking in the
early secretory pathway of A4 cells.
A4 Cells Constitutively and Selectively Degrade PrP from
the ER
To identify the altered step(s) in PrP expression in A4 cells,
we examined the biosynthesis and trafﬁcking of the stably
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For comparison, we used the previously characterized C3
cell line (derived from the same parental N2a cells at the
same time as A4 cells) that stably expresses wild-type PrP.
Ordinarily, PrP [and PrP(A117V)] expressed in N2a cells is
core glycosylated, folded within a few minutes in the ER
lumen, trafﬁcked via the Golgi to the cell surface within 30
min, and degraded with a t1/2 of 6 h in the endo-lysosomal
system. Transit through the Golgi is accompanied by trim-
ming and modiﬁcation of glycans that is readily assayed by
slower migration of PrP on SDS-PAGE and acquisition of
resistance to EndoH. In contrast to this normal PrP metab-
olism (illustrated by C3 cells), PrP(A117V) synthesized in A4
cells during 10 min of labeling disappeared rapidly (t1/2  1-
2 h) without the appearance of mature glycoforms charac-
teristic of trafﬁcking through the Golgi (Figure 2A). Similar
results were obtained for transiently expressed human PrP
(HuPrP), HA-tagged HuPrP, or two disease-associated C-
terminal PrP mutants (H187R and E200K) transfected into
A4 cells: in each case, PrP was degraded in A4 cells without
detectable generation of mature glycosylated species (Figure
2, B and C). Yet, these constructs were metabolized by a
Figure 1. Altered PrP expression in the A4 mutant cell line. (A) Total cell lysates from N2a cells transiently transfected with either wild type
(WT) or the A117V PrP mutant were separated into detergent soluble (S) and insoluble (P) fractions, resolved by SDS-PAGE, and
immunoblotted using an antibody (3F4) that speciﬁcally detects transfected but not endogenous PrP. The migration of different PrP species
are indicated: Mat, mature PrP containing fully modiﬁed glycans; Imm, Immature PrP containing core or incompletely modiﬁed glycans;
CHO, unglycosylated PrP. Bottom panels, the corresponding indirect immunoﬂuorescence images using the 3F4 antibody. (B) Immunoblot
analysis of the parental N2a cells and two derived cell lines (C3 and A4) that stably express WT or PrP(A117V), respectively. The left panel
was probed with 3F4 to detect expression of the stably transfected product, and the right panel with PrP-A (a pan-PrP antibody) to detect
both endogenous and transfected products. (C) Indirect immunoﬂuorescent localization of PrP in C3 and A4 cells using the 3F4 antibody.
Identical detector settings were used to allow comparison of relative expression levels. The lower panels show single cells to illustrate the
different PrP localization patterns in C3 versus A4 cells, the latter of which colocalized with RFP-KDEL, an ER marker introduced by transient
transfection. (D) A4 and parental N2a cells were transiently transfected with plasmids encoding either WT or A117V PrP and analyzed by
fractionation and 3F4 immunoblotting as in A. (E) Total cell lysates from A4 and N2a cells transiently transfected with WT PrP were digested
with EndoH (E), with PNGase F (P) or left untreated () before immuoblotting with 3F4. The lower panel shows this immunoblot stripped
and reprobed with an antibody against TRAP, an ER resident glycoprotein. (F) A4 and parental N2a cells were transiently transfected with
WT PrP and analyzed by indirect immunoﬂuorescence using 3F4. Note the lack of surface expression in A4 cells, in which all of the PrP
colocalized with RFP-KDEL (bottom panels).
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mature PrPs were readily generated as the primary product
during the chase period.
As the initial biosynthesis of PrP (judged by the glycosyl-
ation pattern and amount synthesized at the pulse-point)
was the same in A4 and N2a cells, we inferred that the defect
in A4 cells was at a step after successful PrP translocation
into the ER lumen. Furthermore, the reduced half-life and
lack of Golgi-speciﬁc glycan modiﬁcations suggested that
PrP may be retained in the ER and degraded by ERAD in A4
cells. Typically, glycoproteins subjected to ERAD are pro-
cessed by mannosidase I, retrotranslocated into the cytosol,
deglycosylated by N-glycanse, and degraded by the ubiq-
uitin-proteasome system. To test the involvement of this
pathway in PrP degradation by A4 cells, we analyzed PrP
metabolism upon inhibition of ERAD at two distinct steps
with either a proteasome inhibitor (MG132) or mannosidase
I inhibitor (kifunensine). Both treatments led to the stabili-
zation of PrP (in both steady-state and pulse-chase experi-
ments), with accumulation of different forms: an unglycosy-
lated species with MG132, and a core-glycosylated species
with kifunensine (Figure 2, D and E). Importantly, pulse-
chase analysis in MG132-treated cells showed a clear con-
version of core-glycosylated PrP into unglycosylated PrP
over time, deﬁnitively illustrating PrP retrotranslocation
from the lumen (where it is glycosylated) to the cytosol
(where it is deglycosylated).
Similar results were seen for exogenously transfected Hu-
PrP and mutants (H187R and E200K), suggesting that all
PrPs are routed to ERAD in A4 cells (Figure 2F). Impor-
tantly, even upon prolonged inhibition of PrP degradation
in A4 cells overexpressing any of these PrPs, mature forms
did not appear. Rather, the accumulated PrP was exclusively
in immature forms, suggesting that the lack of mature PrP
expression was not simply a consequence of rapid routing
into ERAD before exit from the ER. Congruent with these
biochemical data, immunoﬂuorescent detection of PrP in
MG132-treated A4 cells showed no detectable surface ex-
Figure 2. Constitutive ERAD of PrP in A4 cells. (A) Pulse-chase analysis of the stably transfected PrP products (immunoprecipitated using
3F4) in either A4 or C3 cells. Pulse labeling with [35S]methionine was for 10 min, followed by chase for the indicated times (in hours). (B and
C) A4 and parental N2a cells were transiently transfected with the indicated constructs and analyzed by pulse chase as in A. The samples
in B were immunoprecipitated with 3F4, whereas the HA-tagged proteins in C were recovered using anti-HA antibody. (D) Pulse-chase
analysis of A4 cells performed in the absence or presence of a proteasome inhibitor (5 M MG132) or mannosidase I inhibitor (1 M
kifunensine). (E) Steady-state levels of PrP in A4 cells (detected using 3F4) after treatments with MG132 or kifunensine for the indicated times
(in hours). (F) Pulse-chase analysis of A4 cells transiently transfected with the indicated mutant PrPs performed in the absence or presence
of proteasome inhibitor (5 M MG132). (G) Indirect immunoﬂuorescence (using 3F4) of A4 cells before and after treatment with 5 M MG132
f o r4h .
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ness of cells detectably expressing PrP (Figure 2G). Thus,
wild-type and mutant PrPs are efﬁciently recognized and
routed into the classical ERAD pathway in A4 cells, despite
the fact that these same mutants are poorly degraded by
ERAD upon misfolding in N2a cells. This routing into ERAD
is apparently via a high capacity pathway because it was
observed (albeit with a lower rate) even in the transient
transfection experiments that grossly overexpress PrP. Fur-
thermore, the normal cell morphology and growth kinetics
of A4 cells relative to the parental cells (data not shown)
suggested a relatively speciﬁc effect on a subset of total
proteins (including PrP), because constitutive degradation
of all glycoproteins or defects in ER-to-Golgi trafﬁcking
would be incompatible with viability.
The GPI Anchoring Signal Sequence Is Required for ERAD
of PrP in A4 Cells
To gain insight into the basis of PrP degradation in A4 cells,
we examined the relative substrate speciﬁcity of constitutive
ERAD. Pulse-chase analysis of total glycoproteins (captured
using concanavalin A) in A4 cells revealed no major differ-
ences in the proﬁle of proteins, their relative amounts of
synthesis, or half-lives compared with the parental N2a cells
(Figure 3A). Analysis of speciﬁc model membrane proteins
including GFP-tagged vesicular stomatitis virus G-protein
(VSVG-GFP) and GFP-tagged endothelin-B receptor (ETBR-
GFP) showed apparently normal maturation in A4 cells
compared with the control N2A cells. Both glycoproteins
had similar kinetics of maturation (as judged by glycan
modiﬁcations), half-lives of degradation, and steady-state
localization at the plasma membrane and endomembrane
system (Figure 3, B and C).
Unlike these (and most) glycoproteins, PrP contains a GPI
anchor. We therefore asked if GPI-anchored proteins in gen-
eral are targeted for ERAD in A4 cells. Pulse-chase analysis
of a minimal GPI-anchored protein, GFP-GPIFR (GFP with
the folate receptor GPI signal), in A4 and N2A cells showed
comparable expression levels and turnover kinetics (Figure
4A). However, a subtle difference in the migration of the
GFP-GPI FR species between the two cell types suggested
some difference in modiﬁcation, prompting us to examine its
localization by confocal microscopy. GFP-GPI FR was pre-
dominantly localized to the plasma membrane and Golgi of
N2a cells, but remained entirely in the ER of A4 cells (Figure
4B). Thus, A4 cells are altered in the trafﬁcking of a heterol-
ogous GPI-anchored protein.
Converse to the observations with GFP-GPI FR, conversion
of PrP to a secretory protein by deletion of its GPI-anchoring
signal sequence (PrP-GPI) normalized its metabolism in A4
cells. Anchorless PrP was synthesized, core glycosylated
(albeit inefﬁciently as described previously; Campana et al.,
2007), and secreted into the medium in both A4 and parental
N2a cells with equal efﬁciency (Figure 4C). PrP(A117V) ex-
pressed in the same A4 cells as PrP-GPI was completely
degraded without any secretion into the media. Reintroduc-
ing an unrelated GPI anchor (from the Qa protein) onto PrP
(PrP-Qa) restored the differences between the N2a and A4
cells (Figure 4D). These ﬁndings suggested that A4 cells are
selectively deﬁcient in the proper trafﬁcking and/or metab-
olism of proteins that contain a GPI-anchoring signal se-
quence. For PrP, ER retention and ERAD in A4 cells can be
Figure 3. Normal glycoprotein metabolism in A4 cells. (A) The synthesis and turnover of total glycoproteins (captured using immobilized
concanavalin-A) was assessed in A4 and N2a cells using pulse-chase analysis. Pulse labeling with [35S]methionine was for 15 min, followed
by chase for the indicated times (in hours). The positions of molecular weight markers (in kDa) are indicated on the left. (B) Synthesis and
turnover of VSVG-GFP and ETBR-GFP in A4 and parental N2a cells was followed by pulse-chase analysis as in Figure 2A. Immunopre-
cipitation was with anti-GFP antibody. (C) Representative ﬂuorescence images of A4 and N2a cells transfected with VSVG-GFP and
ETBR-GFP.
Ashok and Hegde
Molecular Biology of the Cell 3468bypassed by deleting the GPI-anchoring signal sequence,
whereas the addition of a GPI signal to GFP was sufﬁcient to
alter its trafﬁcking.
Degradation of PrP in A4 Cells Is Due to Lack of
Addition of a GPI Anchor
Requirement of the GPI-anchoring sequence for altered PrP
metabolism in A4 cells can be explained in two possible
ways. One possibility is that the A4 cells are defective in the
trafﬁcking of GPI-anchored proteins out of the ER. In this
view, GPI-anchored proteins are retained in the ER despite
their proper maturation and, depending on features of the
mature protein, are routed for ERAD. Alternatively, A4 cells
could be defective in the correct processing of the GPI signal
sequence. Hence, substrates would either remain unproc-
essed or modiﬁed with an immature GPI anchor, resulting in
a feature that could be recognized for ER retention and
degradation.
Several observations argued for a processing rather than
trafﬁcking defect. First, prolonged retention of PrP in the ER
with BFA was insufﬁcient to route PrP for ERAD in N2a cells
(Figure 5A). Second, PrP synthesized in A4 cells (but not in
N2a cells) fractionated predominantly into the aqueous
phase of a TX-114 phase partitioning experiment (Figure 5B),
arguing against an attached lipid. Third, PrP(A117V) syn-
thesized in A4 cells migrated slightly slower than PrP-GPI
expressed in the same cells (Figure 4C). And ﬁnally,
PrP(A117V) from A4 cells comigrates precisely with a form
of PrP whose N-terminal signal has been removed, but
whose C-terminal GPI anchor signal had not be processed
(Figure 4E). These data indicate that PrP made in A4 cells
does not contain the hydrophobic GPI lipid anchor and
based on its migration, retains an uncleaved GPI-anchoring
signal sequence. Retention of the GPI signal would also
explain the difference in migration seen with GFP-GPI FR
expressed in A4 versus N2a cells. Thus, A4 cells are defec-
tive in GPI processing such that an unprocessed GPI signal
sequence may be retained on the substrate, leading to its
altered trafﬁcking and metabolism.
Processing of the GPI-anchoring signal is mediated by the
ER resident GPI-transamidase enzyme complex that recog-
nizes and cleaves the signal on a substrate and replaces it
with a preassembled GPI anchor. Hence, the presence of an
uncleaved GPI signal sequence in A4 cells could be due to
either a defective transamidase enzyme or the inability to
synthesize a fully mature GPI lipid anchor. To distinguish
between these possibilities, we performed TLC of glycolip-
ids from A4 cells labeled with [3H]mannose. As controls, we
used the glycolipid proﬁle of the parental N2a cells (as a
marker for mature GPIs) and lipids from a cell line known to
be defective in the ﬁrst step of GPI anchor biosynthesis
(LM-TK cells or L-cells) as a control for non-GPI mannose-
containing lipids. Neither L-cells nor A4 cells contained the
Figure 4. The GPI-anchoring signal sequence is necessary for
ERAD of PrP in A4 cells. (A) The turnover of GFP-GPIFR was
analyzed in transiently transfected A4 and N2a cells by pulse-chase
labeling and immunoprecipitation (with anti-GFP). Pulse labeling
was for 15 min, followed by chase for the indicated times (in hours).
(B) Left, ﬂuorescence images of A4 and N2a cells transfected with
GFP-GPIFR; right, enlarged views of A4 and N2a cells cotransfected
with GFP-GPIFR (in green) and RFP-KDEL (in red). Yellow indicates
colocalization of the two proteins. (C) The metabolism of PrP lack-
ing the GPI-anchoring signal sequence (PrP-GPI) was determined
in A4 and parental N2a cells by pulse-chase analysis followed by
immunoprecipitation of cell lysates (L) and culture media (M) with
3F4. Labeling was for 10 min, followed by chase for either 0 or 6 h.
The positions of stably expressed PrP(A117V) and transiently trans-
fected PrP-GPI are indicated by the single and double asterisks,
respectively. (D) Steady-state levels of PrP-Qa in N2a and A4 cells
(detected using 3F4) in the presence () or absence () of MG132 for
6 h. (E) Unglycosylated PrP from tunicamycin-treated A4 cells was
compared in its migration to in vitro–synthesized full-length PrP
(FL), PrP lacking the N-terminal signal sequence (SS), or PrP
lacking both the N- and C-terminal signals (/). PrP was detected
by immunoblotting using the 3F4 antibody.
Figure 5. A4 cells are defective in GPI signal processing rather
than post-ER trafﬁcking. (A) Pulse-chase analysis of transiently
transfected WT PrP in N2a cells in the absence () or presence ()
of 10 g/ml brefeldin A (BFA), a drug that prevents ER-to-Golgi
trafﬁcking. (B) Total lysates (T) from untransfected A4 and N2a cells
were prepared in TX-114 containing buffer and separated into aque-
ous (A) and hydrophobic (H) phases. These samples were immu-
noblotted with the PrP-A antibody. Note that recovery of material
from the hydrophobic phase is less efﬁcient under our assay condi-
tions. The asterisk denotes a nonspeciﬁc soluble protein detected by
the PrP-A antibody that serves as a control for complete and com-
parable recovery of proteins from the aqueous phase of both cell
types.
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panel). Even upon overexposure of the TLC (right panel),
mature GPI lipid could not be observed in the A4 cells,
although putative immature species could now be seen (as-
terisks, Figure 6A). This argues that the efﬁcient routing of
PrP (and various mutants) to ERAD in A4 cells can be traced
to a deﬁciency in mature GPI anchors, leading to deﬁcient
GPI transamidation and an uncleaved GPI-anchoring signal
sequence that routes PrP for ERAD.
To further validate and generalize this conclusion, we
performed two additional experiments. First, we analyzed
PrP metabolism in the GPI anchor defective L-cells in which
PrP is predicted to be routed for constitutive ERAD exactly
as in A4 cells. Steady-state analysis of the endogenous PrP
expressed in these mouse ﬁbroblasts revealed only imma-
ture glycoforms that comigrated with PrP made in A4 cells
(Figure 6B). Pulse-chase analysis revealed that L-cells syn-
thesize and target PrP for degradation with approximately
the same kinetics as in A4 cells (Figure 6C). In both steady-
state and pulse-chase experiments, treatment with MG132
and kifunensine conﬁrmed that L-cells employ the classical
ERAD pathway (Figure 6D). Second, we generated a PrP
mutant that cannot be transamidated because of the intro-
duction of a bulky residue at the 1 position of the GPI-
anchoring sequence [PrP(S232W); Kodukula et al., 1993]. On
expression in normal N2a cells, PrP(S232W) was synthesized
exclusively in immature forms and was expressed at very
low steady-state levels. Treatment with MG132 or kifu-
nensine resulted in stabilization of immature PrP forms,
suggesting that PrP(S232W) was subject to constitutive
ERAD in normal cells (Figure 6E). Pulse-chase analysis of
PrP(S232W) in the absence and presence of MG132 con-
ﬁrmed its constitutive degradation by a proteasome-depen-
dent pathway (Figure 6F). Taken together, these data dem-
onstrate that wild-type and mutant PrPs can be routed
extremely efﬁciently into the retrotranslocation and ERAD
pathway by preventing normal processing of the GPI-an-
choring signal. Consistent with this conclusion, a genetic
disease causing PrP mutant (Q217R) that partially interferes
with GPI signal sequence processing leads to ER retention of
the unprocessed PrP (Singh et al., 1997).
A Role for the Mature Domain in the Fate of
Misprocessed GPI-anchored Proteins
GFP-GPI FR is not substantially shortened in its half-life in
A4 cells (relative to N2a cells) and has a much slower turn-
over rate than PrP (compare Figures 2A and 4A). Yet, both
proteins are efﬁciently retained in the ER and prevented
from trafﬁcking to the cell surface in A4 cells. These obser-
vations indicated that a GPI-anchoring signal is not in itself
sufﬁcient to direct a substrate efﬁciently to ERAD, suggest-
ing a role for the mature domain in determining the fate of
unprocessed GPI-anchored proteins. Indeed, GFP-GPIFR
turnover in A4 cells, despite its retention in the ER, does not
occur via a pathway sensitive to proteasome inhibition (Fig-
ure 7A). Surprisingly, even the addition of a glycan at any of
three different positions on GFP-GPIFR (GFP-GPI-CHO) was
insufﬁcient to increase the degradation rate of GFP-GPI FR or
route any of it into a pathway that is inhibitable by either
kifunensine or MG132 (Figure 7A). Similar results were seen
with two other GFP-GPI-CHO constructs with glycans at
different positions (data not shown). Conversely, preventing
the glycosylation of PrP by tunicamycin treatment of A4
cells had no effect on its rate of degradation (Figure 7B).
Thus, although glycosylated PrP follows (at least partially)
an ERAD pathway that is sensitive to inhibitors of glycan
trimming, a glycan is not obligatory for ERAD of PrP with
an unprocessed GPI-anchoring signal sequence.
We also considered the possibility that the PrP GPI se-
quence contained a unique feature not shared by other GPI
sequences, which could be used to route the protein for
ERAD. To test this idea, we generated a GFP-GPI construct
using the GPI signal sequence from PrP (GFP-GPIPrP). Pulse-
chase analysis showed that GFP-GPIPrP, similar to GFP-
GPIFR and in contrast to PrP, is refractory to rapid degrada-
tion in A4 cells (Figure 7C). This demonstrates that the PrP
GPI signal sequence is not the sole determinant of ERAD for
PrP because a heterologous protein cannot be routed for
Figure 6. Defects in GPI anchor biosynthesis in A4 and L-cells
routes PrP for ERAD. (A) A4, N2a, and GPI anchor-deﬁcient L-cells
were labeled with [3H]mannose for 2 h, extracted with organic
solvent to isolate the glycolipid fraction, and analyzed by TLC and
autoradiography. The arrowhead points to the fully mature GPI
lipid anchor, the major mannose-containing lipid in N2a cells that is
lacking in both A4 and L-cells. The darker exposure on the right
revealed several presumably immature mannolipid species (aster-
isks) present in A4 cells that are not found in L-cells. O, origin; F,
solvent front. (B) Total cell lysates from untransfected A4, N2a, C3
and L-cells were immunoblotted using the PrP-A antibody to detect
steady-state levels of endogenously expressed PrP. (C) Biosynthesis
and maturation of endogenous PrP in A4 and L-cells were assessed
by pulse-chase analysis followed by immunoprecipitation using the
PrP-A antibody. Pulse labeling with [35S]methionine was for 10 min,
followed by chase for the indicated times (in hours). (D) Steady-
state levels of PrP in L-cells (detected using PrP-A antibody) after
treatments with 5 M MG132 or 1 M kifunensine for the indicated
times (in hours). (E) Steady-state levels of PrP(S232W) in N2a cells
(detected using 3F4) after treatments with 5 M MG132 (M) or 1 M
kifunensine (K) for 4 h. U, untreated cell lysates. Untreated lysates
from WT PrP expressing cells are shown for comparison (WT). (F)
Pulse-chase analysis of WT and PrP(S232W) in N2a cells performed
in the absence () or presence ()o f5M MG132.
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highly efﬁcient ERAD in A4 cells requires not only an un-
processed GPI-anchoring signal sequence, but also as yet
unidentiﬁed features of the mature domain that are found in
PrP, but not in GFP. Neither the PrP mature domain (e.g.,
PrP-GPI) nor a GPI-anchoring sequence (e.g., GFP-GPIFR
and GFP-GPIPrP) alone was sufﬁcient for efﬁcient ERAD in
A4 cells. Only when PrP contains an unprocessed GPI-
anchoring signal (either its native sequence or the one from
Qa) is it routed for efﬁcient ERAD.
As targeting of misfolded or misprocessed proteins for
ERAD is thought to be mediated by coassociating chaperones
(Nakatsukasa and Brodsky, 2008), it seemed plausible that the
different fates of PrP and GFP-GPI FR involved differences in
their associations. Nondenaturing immunoprecipitations of
PrP and GFP-GPIFR from radiolabeled A4 cells (Figure 7E) did
in fact reveal differences in coprecipitating proteins (the iden-
tities of which remain unknown). One potential difference
could be an association with protein disulﬁde isomerase (PDI),
an oxido-reductase and chaperone known to make contact
with PrP during its initial biosynthesis at the ER (Kim and
Hegde, 2002). By contrast, GFP does not contain any disulﬁde
bonds, and, based on sequential immunoprecipitation experi-
ments, does not seem to coassociate with PDI (data not shown).
This raised the possibility that PDI (and/or related oxido-
reductases) might play a role in the differential routing of PrP
and GFP-GPIFR to ERAD in A4 cells.
To test this idea, we analyzed ERAD of PrP in pulse-chase
experiments performed on A4 cells under reducing conditions
(with 10 mM DTT) that inhibit the chaperone activity of PDI
(Tsai et al., 2001). PrP degradation was completely inhibited
under these conditions, but was largely restored upon removal
of the reducing agent (Figure 7D). This effect was not simply a
consequence of ER stress caused by reducing conditions, be-
cause stress induced by a different method (ER Ca2 depletion
by thapsigargin) did not preclude PrP degradation (Figure 7D).
Furthermore, we could demonstrate by sequential IP analyses
that at least a proportion of PrP is coassociated with PDI in
pulse-labeled A4 cells (Figure 7F). These results are consistent
with the involvement of redox-sensitive factor(s) in the routing
of PrP for ERAD. As PrP, known to interact with PDI during its
biosynthesis, can be coprecipitated with PDI from A4 cells, the
PDI chaperone cycle is inhibited by reducing conditions (Tsai et
al., 2001) and PDI cysteine-mutants have been shown to be
retained in the ER by PDI (Capellari et al., 1999), PDI is a
plausible candidate for facilitating ERAD of PrP. Furthermore,
this could also explain the lack of ERAD for GFP-GPIFR be-
cause this protein does not contain disulﬁde bonds in its folded
state and does not seem to interact with PDI. Although the
mechanistic details of the pathway(s) used for PrP degradation
in A4 cells remain to be elucidated, the comparative analyses of
PrP and GFP-GPIFR have revealed an unanticipated heteroge-
neity in the fate of misprocessed GPI-anchored proteins that
depends directly on features of the mature domain, perhaps as
a consequence of its different chaperone interactions.
DISCUSSION
In this study, our analysis of the A4 mutant cell line that
arose spontaneously as a consequence of stable overexpres-
sion of disease-causing mutant PrP led to the identiﬁcation
of a pathway for highly efﬁcient posttranslational attenua-
Figure 7. The mature domain inﬂuences the
fate of proteins with unprocessed GPI signals.
(A) Pulse-chase analysis in A4 cells of GFP-
GPIFR or its glycosylated counterpart (GFP-
GPI-CHO) in the absence (Unt.) or presence of
5 M MG132 (MG.) or 1 M kifunensine
(Kif.). Pulse labeling was for 10 min and chase
for either 0 or 6 h. The percent of protein
degraded by 6 h was quantiﬁed by phospho-
rimaging and is indicated below each set of
lanes. (B) Pulse-chase analysis of PrP turnover
in A4 cells in the absence or presence of 10
g/ml the glycosylation inhibitor tunicamy-
cin. (C) Pulse-chase analysis of GFP-GPIPrP
(left panels) and GFP-GPIFR (right panels) in
A4 cells. Top panels, PrP immunoprecipita-
tions using the 3F4 antibody; bottom panels,
GFP immunoprecipitations. (D) Pulse-chase
analysis of transiently transfected WT PrP in
A4 and N2a cells in the absence (Unt.) or
presence of the reversible reducing agent, di-
thiothreitol (DTT; 10 mM). /DTT indicates
samples that were labeled in the presence, but
chased in the absence of DTT. The right panel
shows the turnover of WT PrP in A4 cells in
the absence (Unt.) or presence of ER stress
induced by thapsigargin treatment (Tg; 1
M). (E) Metabolically labeled cell lysates
from A4 cells transfected with GFP-GPIFR
were immunoprecipitated under nondenatur-
ing conditions using either the PrP-A anti-
body (left lane) or an anti-GFP antibody (right
lane), to detect coassociating proteins. The ar-
rowhead points to the migration of PrP and
GFP. Asterisks mark coassociating proteins that are enriched in either the PrP or GPI-GFP immunoprecipitates. (F) Metabolically labeled A4
cell lysates were immunoprecipitated with PrP-A, anti-GFP, or anti-protein disulﬁde isomerase (PDI) antibodies under nondenaturing
conditions (1st IP) followed by denaturation and reimmunoprecipitation with the PrP-A antibody (2nd IP). The arrowhead shows the
presence of PrP in the sample that was sequentially immunoprecipitated with anti-PDI and PrP-A antibodies.
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the synthesis of mature GPI lipid anchors with consequent
misprocessing of GPI-anchored proteins. The fate of a GPI-
anchored protein in A4 cells was found to be surprisingly
dependent on the mature domain, indicating a previously
unanticipated heterogeneity in the QC pathways that dis-
pose of proteins containing unprocessed GPI-anchoring sig-
nal sequences. In the case of PrP and disease-causing PrP
mutants, failure to process the GPI-anchoring signal se-
quence leads to its quantitative retrotranslocation and pro-
teasome-dependent degradation by a redox-sensitive path-
way possibly involving PDI family members. By contrast, a
heterologous GPI-anchored protein was retained in the ER
and turned over with slow kinetics by an as yet uncharac-
terized nonproteasomal pathway. Our results illustrate the
utility of somatic cell mutant generation and analyses as a
means for uncovering adaptive pathways of toxic protein
down-regulation. The implications of these ﬁndings for PrP-
associated diseases, as well as general insights into the QC of
GPI-anchored proteins are discussed in subsequent sections
below.
Implications for PrP Biology
Combined with previous data on PrP metabolism, GPI an-
chor addition, and ERAD pathways, our results suggest a
working model for the regulation of PrP degradation and
trafﬁcking by GPI signal sequence transamidation (Figure 8).
During its cotranslational translocation into the ER lumen
(step 1), PrP makes contacts with chaperones including PDI
(Kim and Hegde, 2002). On completion of synthesis, the
GPI-anchoring signal sequence (which is typically not hy-
drophobic or long enough to form a transmembrane do-
main) is transported through the translocon into the ER
lumen (Dalley and Bulleid, 2003) before interacting with the
GPI8 subunit of the GPI transamidase complex (Spurway et
al., 2001; Vidugiriene et al., 2001; Chen et al., 2003). When
fully assembled GPI anchors are available, the signal-trans-
amidase-GPI anchor complex undergoes a concerted cleav-
age and transamidation reaction that replaces the GPI signal
sequence with the GPI anchor (steps 2 and 3; Orlean and
Menon, 2007). In the absence of GPI anchors (e.g., in A4 or
L-cells), PrP retains the GPI signal sequence and, based on
coimmunoprecipitation analysis (Figure 7F), may remain in
association with chaperones including PDI. We postulate
that an inability of PrP to fold correctly in the presence of an
unprocessed GPI signal sequence allows its prolonged asso-
ciation with the PDI-containing chaperone complex. This
association presumably maintains PrP molecules (including
various mutants) in a largely unfolded state that contempo-
rary models posit is needed for retrotranslocation. Subse-
quently, an interaction between PDI and Derlin (Bernardi et
al., 2007; Schelhaas et al., 2007) would deliver PrP substrates
to the retrotranslocation machinery for export out of the ER,
ubiquitination, deglycosylation, and proteasomal degrada-
tion (steps 4 and 5).
For some substrates or under some conditions, a failure in
transamidation may lead the GPI signal sequence to insert
into the membrane as a transmembrane segment (Waneck et
al., 1988). For PrP, such insertion might shield the hydro-
phobic GPI anchor signal in the lipid bilayer, thereby allow-
ing the mature domain to fold correctly and trafﬁc to the cell
surface (Kaneko et al., 1997). Hence, the key event in routing
unprocessed PrP for degradation could be an uncleaved GPI
signal that remains unshielded by the membrane. Another
potential route for PrP to escape the ER in GPI-deﬁcient cells
is if the transamidation reaction proceeds with another nu-
cleophile (such as water), as can occur for model GPI pro-
teins in vitro (Maxwell et al., 1995) and in some cases, in vivo
(Lisanti et al., 1991). In this instance, PrP would essentially be
anchorless, resulting in its secretion (Campana et al., 2007;
dotted arrows, step 3).
This model indicates that preventing processing of the
GPI signal sequence from PrP can be used to posttransla-
tionally attenuate its expression. Although inhibiting all or
most GPI signal processing (as occurs in L-cells or A4 cells)
is presumably not a viable therapeutic strategy in vivo, our
results point to the interaction between GPI transamidase
and the GPI-anchoring signal sequence of PrP (step 2 in
Figure 8) as a potentially selective step for perturbation.
The transamidase-signal interaction is poorly understood
at present, but appears to depend critically on a central
hydrophobic core common to all GPI-anchoring signal
sequences. Despite this shared feature, GPI signals are
highly variable from substrate to substrate and typically
show little or no sequence homology to each other. This
means that although general biophysical parameter(s)
such as overall hydrophobicity are being recognized, each
signal–transamidase interaction is unique in subtle ways.
Figure 8. Working model for the regulation
of PrP degradation and trafﬁcking by GPI signal
sequence transamidation. (1) Interaction of PrP
with PDI (green) during cotranslational translo-
cation into the ER. (2) Recognition of and inter-
action with the GPI-anchoring signal se-
quence (red) by the GPI transamidase
enzyme complex (blue) leads to the replace-
ment of the GPI signal sequence with a
preassembled GPI lipid anchor in cells (e.g.,
N2a) where GPI anchor biosynthesis is in-
tact (3). This lipid anchored PrP species is
now competent for ER exit. PrP species that
contain a GPI signal sequence that is inserted
into the ER membrane as a transmembrane
segment and anchorless PrP generated by
transamidation of the signal by a nucleophile
such as water are also species that remain
competent for trafﬁcking out of the ER. (4) In
cells defective in GPI anchor synthesis (e.g.,
A4 and L-cells) the GPI signal-containing form of PrP may maintain prolonged interactions with chaperones such as PDI. (5) These
interactions eventually deliver misprocessed PrP to the ERAD pathway, perhaps through interaction of PDI with the Derlin associated
retrotranslocation machinery.
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ble to selective small molecule perturbation. Precedent for
this concept was recently provided by studies of N-termi-
nal ER targeting signals which, like GPI signals, share
only general features such as hydrophobicity (von Heijne,
1985) that nonetheless sufﬁce for recognition by both SRP
and the Sec61 translocon (Rapoport, 2007). Remarkably,
this signal-Sec61 interaction was not only shown to differ
subtly from substrate to substrate (Kim and Hegde, 2002),
but also amenable to substrate-selective perturbation by
small molecules (Besemer et al., 2005; Garrison et al., 2005)
that inhibit the activity of only a small subset of signal
sequences. The target of these translocation inhibitors
proved to be Sec61 (MacKinnon et al., 2007), illustrating
that a rather generic recognition event mediated by a
“housekeeping” protein can nonetheless be exploited for
selective inhibition.
Whether down-regulation of PrP via retrotranslocation
and ERAD would be beneﬁcial or detrimental remains a
matter of considerable debate because of cytosolic PrP
(cyPrP) has been suggested to be protective (Roucou et al.,
2003), toxic (Ma et al., 2002; Wang et al., 2005), or inert
(Mironov et al., 2003). The toxicity of cyPrP was further used
to suggest that presumptive low-level retrotranslocation of
disease-causing PrP mutants might be the basis of their
neurodegenerative phenotype. Yet, we found no evidence of
toxicity even when PrP or three independent mutants
(A117V, H187R, E200K) were overexpressed and quantita-
tively routed for retrotranslocation and ERAD. These appar-
ently contradictory results can potentially be explained by
the fact that enforced expression of PrP directly in the cy-
tosol (by deletion of its N- and C-terminal signal sequences)
is qualitatively different from retrotranslocation of PrP from
the ER lumen. The former never enters the ER and is han-
dled by different QC pathways (e.g., cytosolic chaperones)
than proteins retrotranslocated from the ER. Thus, a very
tight coupling of retrotranslocation with ubiquitination and
degradation may essentially never fully expose PrP to the
cytosol during ERAD, whereas signal-deleted PrP would
undergo rounds of attempted folding in the cytosol before
being routed for degradation. Our description of a cleavage-
deﬁcient PrP that undergoes constitutive retrotranslocation
(Figure 6, E and F) could be used to deﬁnitively assess in
transgenic mice the controversial pathological (Ma et al.,
2002) versus protective (Roucou et al., 2003) roles for PrP
retrotranslocation.
Implications for ER Quality Control
An unexpected ﬁnding from this study is that an uncleaved
GPI signal sequence is not sufﬁcient to mediate QC and
ERAD of all proteins by the same pathway. Although an
unprocessed terminal hydrophobic domain would seem to
be an ideal degradation motif, this proved overly simplistic.
A well-folded mature domain such as GFP, while being
retained in the ER, was not retrotranslocated to an appre-
ciable extent. Even the addition of glycans, which presum-
ably alters the chaperones that bind to GFP (Molinari and
Helenius, 2000), did not inﬂuence its degradation. Yet, GFP
is not intrinsically resistant to retrotranslocation because it
has been appended to the lumenal side of transmembrane
proteins that remain competent for ERAD. Thus, the ER
retention mediated by an unprocessed GPI signal sequence
can be uncoupled from its routing into ERAD. This conclu-
sion may help explain why several previous studies on the
fate of unprocessed GPI-anchored proteins have sometimes
arrived at conﬂicting conclusions. For example, an especially
thorough early study of GPI-anchored proteins in anchor-
deﬁcient L-cells demonstrated degradation by a pre-Golgi
pathway (which presumably is the currently known ERAD
pathway) for both native and heterologous proteins
(Delahunty et al., 1993). On the basis of these results, our
ﬁnding of PrP degradation by ERAD in anchor-deﬁcient
cells would seem predictable. Yet, several studies manipu-
lating the GPI anchor of PrP have failed to demonstrate
efﬁcient ERAD (Taraboulos et al., 1995; Kaneko et al., 1997;
Winklhofer et al., 2003; Kiachopoulos et al., 2005), and stud-
ies of other unprocessed GPI-anchored proteins have sug-
gested the involvement of a non-ER, possibly autophagic,
pathway (Field et al., 1994). Similarly, although we ﬁnd that
PrP degradation is inhibited by reducing conditions, other
studies have found these same conditions stimulatory for
degradation of unprocessed GPI-anchored proteins (Wain-
wright and Field, 1997). One reason for these different con-
clusions probably lies in the different substrates being ana-
lyzed in the different studies. Thus, the GPI signal, while
specifying ER retention and degradation, does not do so by
a single mechanism.
A second parameter that may be important in interpreting
these studies involves the means of generating the unproc-
essed GPI-anchored substrate for analysis. Several studies
have analyzed GPI-anchored proteins with a mutated (and
uncleavable) signal as a model. However, it is not always
clear that a mutated anchoring signal would be equivalent in
its metabolism to a native anchoring sequence that fails to be
processed. For example, certain mutants that inhibit cleav-
age do so by essentially converting the GPI signal to a
transmembrane domain (TMD), which for PrP allows its
efﬁcient trafﬁcking to the cell surface (Kaneko et al., 1997).
Similarly, other mutants designed to prevent cleavage may
simultaneously alter the properties of the GPI signal (or
result in cleavage at alternative sites) such that the protein’s
behavior is not directly analogous to an uncleaved native
GPI signal. This may explain why a presumably uncleavable
mutant of the PrP GPI signal led to secretion rather than
ERAD in an earlier study (Winklhofer et al., 2003). Because at
present, the parameters that inﬂuence ER retention and deg-
radation of unprocessed GPI-anchored proteins remain
poorly deﬁned, the use of GPI signal mutants should be
evaluated with caution.
At present, it is not clear how GFP-GPIFR is turned over in
A4 cells and why it is incompetent for ERAD. Typically,
excessive aggregation or saturation of ERAD results in re-
routing to other yet uncharacterized pathways for degrada-
tion of misfolded ER proteins. In this case, neither seems
plausible because the GFP ﬂuorescence was homogeneously
distributed throughout the ER and its expression is compa-
rable to PrP. We have observed that a small proportion of
GFP is secreted into the media after cleavage at a furin-like
protease site near the C-terminus of GFP (data not shown),
but this minor population is insufﬁcient to explain its turn-
over. In stark contrast to GFP-GPIFR, PrP is a robust retro-
translocation substrate regardless of its glycosylation state
or disease-causing mutations. This strong dependence on
the mature domain for the pathway of degradation, together
with the different fates for a GPI-anchoring signal in the
absence of transamidation (step 3 in Figure 8), may explain
otherwise conﬂicting reports regarding the metabolism of
unprocessed GPI-anchored proteins ranging from ERAD,
ER retention, post-ER accumulation, secretion, or cell sur-
face expression. It will therefore be important to now dissect
the parameters of the mature domain that inﬂuence the
pathways of degradation. An important clue in this respect
may be the different chaperone(s) that differentially associate
with proteins of different characteristics. The differential
Prion Protein Retrotranslocation
Vol. 19, August 2008 3473metabolism of PrP and GFP-GPIFR in A4 cells may provide
an important model system to study the distinct pathways
available to unprocessed GPI-anchored proteins for degra-
dation.
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